Table 1.

Characteristics of patients who received an HLA-matched sibling transplant

Variable	Cy/ATG*	Cy ± Flu†	Bu/Cy‡	Flu/Cy/ATG§
N	593	142	85	135
Age, median (range), y	17 (1-59)	20 (1-58)	20 (4-58)	26 (1-58)
Age category, y
<18	331 (56)	52 (37)	33 (39)	51 (38)
18-29	156 (26)	67 (47)	41 (48	27 (20)
≥30	106 (18)	23 (16)	11 (13)	57 (42)
Sex
Male	326 (55)	81 (57)	53 (62)	62 (46)
Female	267 (45)	61 (43)	32 (38)	73 (54)
Performance score
90-100	455 (77)	107 (75)	58 (68)	105 (78)
≤80	124 (21)	30 (21)	26 (31)	26 (19)
Not reported	14 (2)	5 (4)	1 (1)	4 (3)
Recipient CMV serostatus
Positive	389 (66)	124 (87)	73 (86)	102 (76)
Negative	198 (33)	14 (10)	9 (11)	31 (23)
Not reported	6 (1)	4 (3)	3 (4)	2 (1)
Interval diagnosis to transplant, mo
≤3	369 (62)	96 (68)	32 (38)	64 (47)
>3	224 (38)	46 (32)	53 (62)	71 (53)
Donor-recipient sex match
Female to male	145 (24)	27 (19)	22 (26)	32 (24)
Other	448 (76)	115 81)	63 (74)	103 (76)
GVHD prophylaxis
Cyclosporine + methotrexate	371 (63)	126 (89)	81 (95)	99 (73)
Cyclosporine + mycophenolate	18 (3)	2 (1)	—	7 (5)
Cyclosporine alone	55 (9)	4 (5)	3 (4)	3 (2)
Tacrolimus + methotrexate	135 (23)	7 (5)	1 (1)	8 (6)
Tacrolimus + mycophenolate	14 (2)	—	—	18 (13)
Transplant period
2000-2004	130 (22)	45 (32)	43 (51)	7 (5)
2005-2008	102 (17)	38 (27)	17 (20)	31 (23)
2009-2014	361 (61)	59 (42)	25 (29)	97 (72)
Follow-up, median (range), mo	61 (3-188)	70 (3-187)	72 (6-197)	36 (6-119)

Values are n (%) unless otherwise noted.

^*Cy dose: 200 mg/kg (n = 553), 150 mg/kg (n = 19), 100 mg/kg (n = 2), 50 mg/kg (n = 19).

^†Cy dose: 200 mg/kg (n = 116), 150 mg/kg (n = 15), 100 mg/kg (n = 1).

^‡Cy dose: 200 mg/kg (n = 5), 100 mg/kg (n = 80).

^§Cy dose: 200 mg/kg (n = 10), 100 mg/kg (n = 112), 50 mg/kg (n = 13).